Related Experiment Videos
Clinical study of multi-drug resistance gene (MDR1) expression in primary ovarian cancer
1Department of Obstetric and Gyneocology, Tongji Hospital, Tongji Medical University, Wuhan.
Abstract:
This study was designed to measure the multi-drug resistance gene (MDR1) mRNA content and analyze clinical relationship between MDR1 expression and drug resistance in primary ovarian cancer. Reverse transcription PCR (RT-PCR) was used to measure MDR1 mRNA content in biopsy sample of 31 primary ovarian cancers (experimental group) and 30 gynecological tumors (control group). The level of 95.2% (20/21) MDR1 expression was relatively low, and the detected rate of MDR1 expression was 67.7% (21/31) in experimental group, which was higher than that in control group (40.0%, P < 0.05). The differences of MDR1 expression between the effective group and no effect group after combined chemotherapy was significant (P < 0.05). No significant relationship was found between MDR1 expression and clinical stage or histological classification or grade of differentiation in experimental group. We are led to concluded that primary ovarian cancers have drug-resistance clones which might express MDR1 spontaneously and expression of MDR1 may be used as a prognostic and predictive indicator for clinical response of ovarian cancers to combined chemotherapy.
Insights
This study found that multi-drug resistance gene (MDR1) expression is higher in ovarian cancer patients, indicating potential drug resistance. MDR1 expression may predict treatment effectiveness in ovarian cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ovarian cancer often exhibits resistance to chemotherapy.
- The multi-drug resistance gene (MDR1) is implicated in drug efflux and treatment failure.
Purpose of the Study:
- To quantify MDR1 mRNA levels in primary ovarian cancer.
- To investigate the correlation between MDR1 expression and clinical drug resistance.
Main Methods:
- Reverse transcription PCR (RT-PCR) was employed to measure MDR1 mRNA.
- Biopsy samples from 31 primary ovarian cancers and 30 control gynecological tumors were analyzed.
Main Results:
- MDR1 expression was detected in 67.7% of ovarian cancer samples, significantly higher than controls (40.0%).
- Higher MDR1 expression correlated with a poorer response to combined chemotherapy.
- No significant association was found between MDR1 expression and clinical stage, histology, or differentiation grade.
Conclusions:
- Primary ovarian cancers may possess drug-resistant clones expressing MDR1.
- MDR1 expression serves as a potential prognostic and predictive biomarker for chemotherapy response in ovarian cancer.